李冠兰,彭 涛,郭昌云,余雅婕,朱志林.麝香保心丸与曲美他嗪联合治疗老年冠心病心绞痛的疗效及对血浆BNP水平的影响[J].,2017,17(15):2926-2929 |
麝香保心丸与曲美他嗪联合治疗老年冠心病心绞痛的疗效及对血浆BNP水平的影响 |
Effect of Shexiang Baoxin Pill and Trimetazidine Combined Treatment on Senile Coronary Heart Disease Angina Pectoris and Influence on Plasma BNP Levels |
投稿时间:2016-10-17 修订日期:2016-10-30 |
DOI:10.13241/j.cnki.pmb.2017.15.033 |
中文关键词: 麝香保心丸 曲美他嗪 老年 冠心病心绞痛 疗效 血浆BNP |
英文关键词: Shexiang Baoxin Pill Trimetazidine Senile Coronary heart disease angina pectoris Effect Plasma BNP |
基金项目: |
|
摘要点击次数: 326 |
全文下载次数: 140 |
中文摘要: |
摘要 目的:分析麝香保心丸联合曲美他嗪治疗老年冠心病心绞痛的疗效及对血浆B型脑钠肽 (BNP)水平的影响。方法:选取2010年1月-2015年1月我院收治的老年冠心病心绞痛患者128例作为研究对象,采用随机数字表法将其分为实验组(64例)和对照组(64例),单纯使用曲美他嗪对对照组患者进行治疗,联合使用麝香保心丸和曲美他嗪对实验组患者进行治疗,观察两组患者的临床疗效,比较治疗前后两组血浆BNP水平、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)以及左室射血分数(LVEF),统计两组的不良反应。结果:实验组的治疗总有效率为92.19%,明显高于对照组的62.50% ,差异具有统计学意义(P<0.05);治疗后,实验组与对照组血浆BNP、LVEDD、LVESD、LVEF均得到改善,但是实验组改善更明显,差异具有统计学意义(P<0.05);两组不良反应率比较,无统计学差异(P>0.05)。结论:应用麝香保心丸联合曲美他嗪治疗老年冠心病心绞痛的临床疗效显著,且明显降低血浆BNP水平,值得在临床上推广应用。 |
英文摘要: |
ABSTRACT Objective: To analyze the effect of Shexiang Baoxin Pill combined with trimetazidine in the treatment of senile patients with coronary heart disease angina pectoris and its influence on plasma brain natriuretic peptide(BNP) levels. Methods: 128 cases of senile patients with coronary heart disease angina pectoris treated in our hospital were selected as the objects from January 2010 to January 2015, they were divided into experimental group(64 cases) and control group(64 cases) according to the random number table method. The control group was treated by Trimetazidine, the experimental group was treated by Shexiang Baoxin Pill combined with trimetazidine. Observed and compared the clinical efficacy of the two groups and compared the plasma BNP level, left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter(LVESD) and left ventricular ejection fraction(LVEF) of two groups before and after treatment, analyzed the adverse reations in the two groups. Results: The total effective rate of treatment group was 92.19%, which was significantly higher than 62.50% in control group (P<0.05). After treatment, the plasma BNP level, LVEDD, LVESD, LVEF in experimental group and control group were improved, but the experimental group improved more significantly, and the differences were statistically significant (P<0.05). The incidence of adverse reactions between the two groups had no significant difference(P>0.05). Conclusion: The Shexiang Baoxin Pill combined with trimetazidine has better clinical effect in the treatment senile patients with coronary heart disease angina pectoris, which could significantly decreases the plasma BNP level, it is worthy of clinical application. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |